Ignite Creation Date:
2025-12-24 @ 5:17 PM
Ignite Modification Date:
2026-03-05 @ 3:31 AM
Study NCT ID:
NCT05428150
Status:
COMPLETED
Last Update Posted:
2022-11-14
First Post:
2022-06-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
Sponsor:
Excalibur Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-08
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-09-25
Completion Date Type:
ACTUAL
First Submit Date:
2022-06-15
First Submit QC Date:
None
Study First Post Date:
2022-06-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-11-10
Last Update Post Date:
2022-11-14
Last Update Post Date Type:
ACTUAL